NCYT:LON
Novacyt SA
39,50 GBX
arrow_downward
-0,25%(-0,100) 1D
16 ოქტ, 16:35:25 GMT+1 · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NCYT...
Open
39,60 GBX
High
39,68 GBX
Low
39,20 GBX
Mkt. cap
32,45 მლნ.
Avg. vol.
102,63 ათ.
Volume
12,22 ათ.
52-wk high
86,00 GBX
52-wk low
26,60 GBX
Shares outstanding
37,66 მლნ.
No. of employees
228
Open
39,60 GBX
High
39,68 GBX
Low
39,20 GBX
Mkt. cap
32,45 მლნ.
Avg. vol.
102,63 ათ.
Volume
12,22 ათ.
52-wk high
86,00 GBX
52-wk low
26,60 GBX
Shares outstanding
37,66 მლნ.
No. of employees
228
News stories
From web sources and news partners
Foreign Policy Journal
·
12 წუთის წინ
Fed Rate Decision Creates Diverging Fortunes For Costco (NASDAQ: COST), Walmart (NYSE: WMT) and Target (NYSE: TGT)
Yahoo Finance
·
1 საათის წინ
Nasdaq 100 Records Worst Week In 18 Months As Investors Steer Clear Of Chipmakers — AAPL, MSTR, UBER, SOXX In Focus
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA